Last edition
News about Global Pharma
OneSource Achieves INR 3,926 Million Revenue in Q3FY25
OneSource demonstrated exceptional profitability with EBITDA reaching INR 1,432 million, an 85 percent increase compared to the previous quarter, resulting in a robust EBITDA margin of 36.5 percent, up by 1,334 basis points quarter-on-quarter.
Global Pharma | 01/02/2025 | By Aishwarya | 876
US FDA Approves New Non-Opioid Treatment for Moderate to Severe Acute Pain
The US FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, marking a significant milestone in pain management alternatives.
Global Pharma | 31/01/2025 | By Manvi | 168
UK Biocentre Picks Azenta's BioArc Ultra Automated Storage System to Power Research Excellence
UK Biocentre will utilize the new BioArc Ultra™ to deliver on critical research projects including the United Kingdom’s largest health research program – Our Future Health.
Global Pharma | 31/01/2025 | By Aishwarya | 230
Zydus Takeda Healthcare Celebrates 25 Years of Manufacturing Operations in India
Over the past 25 years, the manufacturing site at Vashi has emerged as a supplier of APIs and intermediates for Takeda’s markets in Europe, Japan, Brazil, and Korea.
Global Pharma | 31/01/2025 | By Aishwarya | 1201
Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25
The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year.
Global Pharma | 31/01/2025 | By Aishwarya | 1612
NATCO Pharma has secured approval for generic Everolimus tablets for oral suspension. The company’s marketing partner for the ANDA, Breckenridge Pharmaceutical plans to launch it in the US market immediately.
Global Pharma | 30/01/2025 | By Abha | 842
Brenntag Pharma Extends Partnership with Citribel for Citric Acids and Citrates Pharma Excipients
In addition to the longtime cooperation on the Pharma markets of France, Spain, Germany and Benelux, Citribel is now offered to Brenntag Pharma customers in Israel, Turkey and South Africa (RSA).
Global Pharma | 29/01/2025 | By Aishwarya | 955
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of USD 250 Million
The addition of Evergreen’s scalable manufacturing capabilities and infrastructure enhances Lantheus’ ability to meet the complex demands of radiopharmaceutical development and production.
Global Pharma | 29/01/2025 | By Aishwarya | 441
Cold Chain Technologies and Tower Cold Chain Achieve Major Sustainability Milestones
The integration of Tower’s expertise in reusable temperature-controlled logistics with CCT’s wide portfolio of solutions and services has led to expanded product offerings and greater innovation.
Global Pharma | 29/01/2025 | By Aishwarya | 383
Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer
The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.
Global Pharma | 28/01/2025 | By Aishwarya | 599
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy